March 22nd 2023
The second pivotal phase 3 data on NOV03 (perfluorohexyloctane) show that NOV30 consistently met primary endpoints for signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.
New technologies in the clinic: Combining light-based therapies for the treatment of dry eye
December 19th 2022When combined, intense pulsed light and low-level light therapy—both of which have roots in dermatology—create a synergistic effect that treat dry eye more effectively than one therapy alone.
Azura Ophthalmics receives grant for leading CLD clinical candidate
September 10th 2022Azura has secured funding to support its 2-stage study evaluating the safety, tolerability, and efficacy of AZR-MD-001, its leading candidate, for patients with contact lens discomfort who show signs of meibomian gland dysfunction.